Medicament composition for treating respiratory disease

A technology for respiratory diseases and compositions, which is applied in the field of pharmaceutical compositions for asthma, and can solve problems such as inconvenient use, slow onset of effect, and large dosage

Inactive Publication Date: 2009-01-21
天津药业集团有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] It can be seen from Table 1 that the commonly used leukotriene receptor antagonists are all oral constant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition for treating respiratory disease
  • Medicament composition for treating respiratory disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Montelukast 20g

[0030] Ethanol 750g

[0031] Propylene glycol 150g

[0032] Dichlorodifluoromethane 1500g

[0033] Preparation process: add the prescribed amount of montelukast into ethanol and propylene glycol, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, seal the dose valve system, and add Inject dichlorodifluoromethane under pressure to obtain the product, theoretically fill 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle is 50 presses, and each press contains 400 μg of montelukast.

Embodiment 2

[0035] Montelukast Sodium 12.5g

[0036] Ethanol 200g

[0037] Glycerol 19.5g

[0038] HFA227 750g

[0039] HFA134a 750g

[0040] Vitamin C 7.5g

[0041] Preparation process: Add the prescribed amount of montelukast into vitamin C, ethanol and glycerol that are evenly stirred, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, and seal the dose The valve system is further pressurized HFA134a and HFA227 respectively, namely, 1000 bottles can be theoretically filled, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. 50 presses per bottle, each press contains 250 μg of montelukast sodium

Embodiment 3

[0043] Montelukast 5g

[0044] Ethanol 750g

[0045] Glycerin 150g

[0046] Dichlorotetrafluoroethane 1500g

[0047] Sodium metabisulfite 7.5g

[0048] Preparation process: Add the prescribed amount of montelukast into the well-stirred sodium metabisulfite, ethanol and glycerin, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, and seal the dose valve system , and pressurize the dichlorotetrafluoroethane respectively to obtain the product, which can be theoretically packed into 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle contains 50 presses, and each press contains 100 μg of montelukast.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for the treatment of respiratory diseases, in particular asthma, rhinitis or COPD and especially asthma. The composition consists of one or a plurality of LTRAs as active ingredients and one or a plurality of pharmaceutical accessories suitable for respirable aerosol and powder and irrespirable aerosol, pressurized spray and powder.

Description

technical field [0001] The invention provides a pharmaceutical composition for treating respiratory diseases, especially asthma, rhinitis or chronic obstructive pulmonary disease (COPD), especially asthma. Background technique [0002] Asthma is a chronic airway inflammation characterized by reversible airway obstruction and increased airway responsiveness. Airway obstruction is caused by two factors: increased secretions caused by bronchial mucosal inflammation, mucosal edema, and smooth muscle spasm stimulated by inflammation; while asthma Increased airway reactivity is also a result of damage to the bronchial epithelium due to airway inflammation. It is recognized that only by controlling the inflammation of the airway mucosa can the ultimate goal of reducing airway hyperresponsiveness and relieving asthma symptoms be achieved. [0003] The pathogenic mechanism of asthma and other respiratory diseases is not yet fully understood, but the allergic slow-response substance ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K9/12A61K31/405A61K31/41A61K31/47A61P11/00A61P11/02A61P11/06A61P37/08
Inventor 郝于田陈松程振国
Owner 天津药业集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap